Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Shuttle Pharmaceuticals means wading through pages of radiation-sensitizer chemistry, trial protocols, and financing footnotes. If finding R&D burn rates or decoding licensing terms inside a 10-K feels overwhelming, you’re not alone.
Stock Titan solves that problem. Our AI surfaces the numbers and narrative that matter—cash runway, Phase 2 milestones, dilution risks—directly from every filing type. Need the Shuttle Pharmaceuticals annual report 10-K simplified? We highlight how Ropidoxuridine’s glioblastoma study influences revenue projections. Curious about a fresh capital raise? The latest Shuttle Pharmaceuticals 8-K material events explained appear with plain-English context the moment EDGAR posts.
Here’s what you’ll find on this page:
- Real-time alerts for Shuttle Pharmaceuticals Form 4 insider transactions real-time, so you can see when executives buy or sell shares.
- Concise AI notes inside every Shuttle Pharmaceuticals quarterly earnings report 10-Q filing, turning trial-cost tables into readable trends.
- Side-by-side comparisons of equity issuances, royalty obligations, and Shuttle Pharmaceuticals proxy statement executive compensation disclosures.
Whether you’re monitoring Shuttle Pharmaceuticals insider trading Form 4 transactions before a data read-out or seeking a quick Shuttle Pharmaceuticals earnings report filing analysis, our platform answers the exact questions professionals ask: “understanding Shuttle Pharmaceuticals SEC documents with AI”. All filings, all the time—explained simply.
Shuttle Pharmaceuticals Holdings, Inc. is registering 625,156 shares of common stock for resale by a single selling stockholder. These shares are issuable upon exercise of a pre-funded warrant that was sold in a November 2025 private placement for approximately $2.5 million of gross proceeds already received by the company, so Shuttle will not receive any cash from the resale of these shares.
Shuttle Pharma is a development-stage oncology company focused on radiation-enhancing therapies, led by its Ropidoxuridine program, which has advanced into a Phase II clinical trial in brain cancer patients undergoing radiation therapy after a completed Phase I study. The company highlights substantial risks, including the potential pressure on its share price from resale of these registered shares and other issuances, as well as a going concern uncertainty noted by its independent auditor. Shuttle is also pursuing a contemplated asset acquisition from Molecule, which it cautions may carry integration and execution risks.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reports that it was out of compliance with Nasdaq’s stockholders’ equity listing rule after disclosing stockholders’ equity of $1,394,161 in its quarterly report for the period ended September 30, 2025, below the $2,500,000 minimum required for the Nasdaq Capital Market. The company states it now believes it has regained compliance based on a private placement completed on November 4, 2025 that raised approximately $2.5 million in gross proceeds before fees and expenses. Nasdaq staff will continue to monitor equity levels, and if the company does not demonstrate compliance with Listing Rule 5550(b)(1) in its next periodic report, its common stock may be subject to delisting.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported third‑quarter results with no revenue and a net loss of $2.35 million. For the nine months ended September 30, 2025, the company recorded a net loss of $9.11 million. Operating expenses were $2.27 million in the quarter, led by research and development of $0.94 million and general and administrative of $0.89 million.
Cash and cash equivalents were $2.09 million at quarter‑end. Total assets were $3.54 million, liabilities $2.15 million, and stockholders’ equity $1.39 million. The company executed multiple financings in 2025, including $5.0 million net proceeds from a March public offering and $3.9 million net from a June private placement with pre‑funded warrants; a $2.0 million revolving note remained undrawn. On November 3, 2025, SHPH closed a private placement of a pre‑funded warrant for gross $2.5 million. Management disclosed substantial doubt about continuing as a going concern. The company also signed a binding term sheet on October 20, 2025 to acquire Molecule’s assets and liabilities for $10,000,000 in cash and stock, subject to definitive agreements and approvals.
Shuttle Pharmaceuticals Holdings, Inc. entered a securities purchase agreement for a private placement of a pre-funded warrant to purchase up to 625,156 shares of common stock, delivering approximately $2.5 million in gross proceeds. The transaction closed on November 4, 2025.
The warrant is immediately exercisable at $0.001 per share and includes a beneficial ownership cap of 4.99%, adjustable up to 9.99% with 61 days’ prior notice. The company agreed to file a resale registration statement within 15 days of the agreement date and to have it declared effective within 45 days (or 75 days if reviewed by the SEC). For 15 days after closing, the company agreed not to issue or announce new equity or file other registration statements, except as contemplated.
WestPark Capital acted as placement agent and received a cash fee equal to 4% of gross proceeds.
Shuttle Pharmaceuticals Holdings (SHPH)Form 3 reflecting beneficial ownership status as of 09/12/2025.
The filing shows 0 shares of common stock held directly and lists no derivative securities. This is an administrative disclosure of insider holdings and does not reflect a transaction.
Shuttle Pharmaceuticals Holdings (SHPH) director filed an initial Form 3 disclosing beneficial ownership as of 09/12/2025. The filing reports 0 shares of common stock beneficially owned and no listed derivative securities. It was filed by one reporting person in the capacity of director, indicating no equity holdings at the time of the event.
Shuttle Pharmaceuticals (SHPH) disclosed two material updates. On October 20, 2025, the company signed a binding term sheet to purchase substantially all assets and liabilities of 1542770 BC Ltd. (Molecule) for $10,000,000, payable over time in a mix of cash and SHPH common stock at the company’s determination and tied to milestones. Closing remains subject to definitive agreements, board approval, and due diligence.
Separately, on October 15, 2025, Theradex Systems, the company’s primary CRO, delivered a notice terminating the 2018 master agreement and demanding immediate payment of $1.091 million. The letter cites a contract provision allowing termination for material breach and states Services will cease if payment is not made within 30 days of the letter. Together, the prospective acquisition outlines a strategic transaction, while the CRO action introduces operational and payment pressure until resolved.
FAQ
What is the current stock price of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the market cap of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
